NCT05011851 - An Open-Label Study of the Safety, Tolerability, and Pharmacokinetics of Oral NNZ-2591 in Angelman Syndrome | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

July 12, 2022

Primary Completion Date

May 13, 2024

Study Completion Date

July 16, 2024

Conditions

Angelman Syndrome

Interventions

DRUG

NNZ-2591

NNZ-2591 oral solution (50mg/mL) to be administered twice daily for 13 weeks.

Trial Locations (3)

Sydney Children's Hospital, Randwick

Austin Health, Heidelberg

Centre for Clinical Trials in Rare Neurodevelopmental Disorders at Children's Health Queensland Hospital and Health Service, South Brisbane